|
 The group said patients treated in its PhaseI/II trial of
donor-derived expanded cardiac stem cells (AlloCSC) showed no
side-effects and all of them continued to live after 30 days, six
months and a year.
Tigenix added that in one subgroup of trial patients associated with
a poor long-term outlook, there was a larger reduction in the size
of infarction, tissue death due to inadequate blood supply.
"This is the first trial in which it has been demonstrated that
allogeneic cardiac stem cells can be transplanted safely through the
coronary tree," one of the doctors in the trial said.
The group said it would now analyze the data from the trial and
decide on how to proceed with its research.
(Reporting by Robert-Jan Bartunek; editing by Philip Blenkinsop)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
